Table 2.

Efficacy data from the CA180-034 phase III dose-optimization study of second-line dasatinib in patients with CML-CP resistant or intolerant to imatinib therapy after a minimum follow-up of 2 years (Shah et al. 2008a, 2010)

Dasatinib dose schedule	n	Patients, %
		CHR	MCyR	CCyR	MMR	PFSa	OS
100 mg once daily	167	92	63	50	37	80	91
70 mg twice daily	168	88	61	54	38	76	88
140 mg once daily	167	87	63	50	38	75	94
50 mg twice daily	168	92	61	50	38	76	90

CCyR complete cytogenetic response, CHR complete hematologic response, MCyR major cytogenetic response, MMR major molecular response, OS overall survival, PFS progression-free survival

^aDefinition of disease progression: loss of previous CHR or MCyR, confirmed AP/BP disease, increasing WBC count (recorded by the investigator as a doubling from the lowest value to >20,000/mm³ or increases of >50,000/mm³ on 2 assessments ≥2 weeks apart), increase in Ph+ metaphases by ≥30 %, or death from any cause